A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)

• Status: Completed
• Trial end date: 2009-04-01

Summary

This is a first-in-man study for the purpose of determining the safety and tolerability of LX214 ophthalmic solution in healthy volunteers and in patients with dry eye syndrome.

• Phase: Phase 1

Details

• Lead Sponsor: Lux Biosciences, Inc.
• Treatments: Ophthalmic Solutions; Pharmaceutical Solutions